Sumitomo Pharma bags world-first go-ahead for iPS cell therapy to treat Parkinson’s disease
The conditional, time-limited approval comes through a joint effort with RACTHERA, a joint venture in which Sumitomo Chemical holds a 66.6% stake and Sumitomo Pharma holds 33.4%




















